This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Etablissment Françis Du Sang, National Institute of Health and Medical Research, Universitéde Strasbourg. Active years: 2022.
Company Filing History:
1 out of 1 
1 out of 1,853 
1 out of 186 
Years Active: 2022
Title: François Lanza: Innovator in Megakaryocyte Research
Introduction
François Lanza is a notable inventor based in Beinheim, France. He has made significant contributions to the field of medical research, particularly in the production of megakaryocyte progenitor cells. His work has implications for the development of therapies related to blood platelets.
Latest Patents
Lanza holds a patent titled "CD34CD41megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets." This invention relates to a method of producing CD34+CD41 megakaryocyte progenitor cells, as well as a substantially pure cell population of megakaryocyte precursor cells obtained by this method. Additionally, the patent describes a method for producing proplatelet-bearing megakaryocytes and/or platelets using the CD34+CD41 cells.
Career Highlights
Throughout his career, François Lanza has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and the Établissement Français du Sang. His research has focused on advancing the understanding and application of megakaryocyte biology.
Collaborations
Lanza has collaborated with notable colleagues, including Catherine Strassel and Christian Gachet. These partnerships have contributed to the advancement of his research and the development of innovative methodologies in the field.
Conclusion
François Lanza's contributions to megakaryocyte research and his patented methodologies highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements in platelet production and related therapies.